BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 25715308)

  • 1. Trimetazidine Decreases Risk of Contrast-Induced Nephropathy in Patients With Chronic Kidney Disease: A Meta-Analysis of Randomized Controlled Trials.
    Nadkarni GN; Konstantinidis I; Patel A; Yacoub R; Kumbala D; Patel RA; Annapureddy N; Pakanati KC; Simoes PK; Javed F; Benjo AM
    J Cardiovasc Pharmacol Ther; 2015 Nov; 20(6):539-46. PubMed ID: 25715308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trimetazidine in the prevention of contrast-induced nephropathy in chronic kidney disease.
    Ibrahim TA; El-Mawardy RH; El-Serafy AS; El-Fekky EM
    Cardiovasc Revasc Med; 2017; 18(5):315-319. PubMed ID: 28532702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical effect of trimetazidine on prevention of contrast-induced nephropathy in patients with renal insufficiency: An updated systematic review and meta-analysis.
    Ye Z; Lu H; Su Q; Guo W; Dai W; Li H; Yang H; Li L
    Medicine (Baltimore); 2017 Mar; 96(9):e6059. PubMed ID: 28248861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trimetazidine in the prevention of contrast-induced nephropathy after coronary procedures.
    Onbasili AO; Yeniceriglu Y; Agaoglu P; Karul A; Tekten T; Akar H; Discigil G
    Heart; 2007 Jun; 93(6):698-702. PubMed ID: 17065180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trimetazidine reduces contrast-induced nephropathy in patients with renal insufficiency undergoing coronary angiography and angioplasty: A systematic review and meta-analysis (PRISMA).
    Heshmatzadeh Behzadi A; Amoozgar B; Jain S; Velasco N; Zahid U; Abbasi H; Alasadi L; Prince MR
    Medicine (Baltimore); 2021 Mar; 100(10):e24603. PubMed ID: 33725824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trimetazidine in the prevention of contrast induced nephropathy after coronary angiogram.
    Rahman MM; Haque SS; Rokeya B; Siddique MA; Banerjee SK; Ahsan SA; Rahman F; Mahmood M; Ahmed K; Bhuiyan MM; Joarder AI; Debnath RC
    Mymensingh Med J; 2012 Apr; 21(2):292-9. PubMed ID: 22561774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coenzyme Q10 combined with trimetazidine in the prevention of contrast-induced nephropathy in patients with coronary heart disease complicated with renal dysfunction undergoing elective cardiac catheterization: a randomized control study and in vivo study.
    Chen F; Liu F; Lu J; Yang X; Xiao B; Jin Y; Zhang J
    Eur J Med Res; 2018 May; 23(1):23. PubMed ID: 29776437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statins for the Prevention of Contrast-Induced Nephropathy After Coronary Angiography/Percutaneous Interventions: A Meta-analysis of Randomized Controlled Trials.
    Liu YH; Liu Y; Duan CY; Tan N; Chen JY; Zhou YL; Li LW; He PC
    J Cardiovasc Pharmacol Ther; 2015 Mar; 20(2):181-92. PubMed ID: 25193735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trimetazidine Prevention of Contrast-Induced Nephropathy in Coronary Angiography.
    Liu W; Ming Q; Shen J; Wei Y; Li W; Chen W; Xu Y
    Am J Med Sci; 2015 Nov; 350(5):398-402. PubMed ID: 26445302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trimetazidine can prevent the occurrence of contrast-induced nephropathy after percutaneous coronary intervention in elderly patients with renal insufficiency.
    Fu H; Zhang J; Zhang H; Zhang P; Fu X; Zeng Z; Zhang X; Li W; Yang S; Liu X; Fu N
    Perfusion; 2021 Sep; 36(6):603-609. PubMed ID: 32909511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of NaCl saline hydration and N-Acetyl Cysteine to prevent contrast induced nephropathy in different populations of patients at high and low risk undergoing coronary artery angiography.
    Calabrò P; Bianchi R; Caprile M; Sordelli C; Cappelli Bigazzi M; Palmieri R; Gigantino G; Limongelli G; Capozzi G; Cuomo S; Calabrò R
    Minerva Cardioangiol; 2010 Feb; 58(1):35-40. PubMed ID: 20145594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials.
    Zagler A; Azadpour M; Mercado C; Hennekens CH
    Am Heart J; 2006 Jan; 151(1):140-5. PubMed ID: 16368307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-acetylcysteine and/or ascorbic acid versus placebo to prevent contrast-induced nephropathy in patients undergoing elective cardiac catheterization: The NAPCIN trial; A single-center, prospective, randomized trial.
    Habib M; Hillis A; Hammad A
    Saudi J Kidney Dis Transpl; 2016 Jan; 27(1):55-61. PubMed ID: 26787567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of trimetazidine on incidence of myocardial injury and contrast-induced nephropathy in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention.
    Shehata M
    Am J Cardiol; 2014 Aug; 114(3):389-94. PubMed ID: 24927970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of theophylline in preventing contrast-induced nephropathy after coronary angiographic procedures.
    Bilasy ME; Oraby MA; Ismail HM; Maklady FA
    J Interv Cardiol; 2012 Aug; 25(4):404-10. PubMed ID: 22612071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS--a multicenter prospective controlled trial.
    Koc F; Ozdemir K; Kaya MG; Dogdu O; Vatankulu MA; Ayhan S; Erkorkmaz U; Sonmez O; Aygul MU; Kalay N; Kayrak M; Karabag T; Alihanoglu Y; Gunebakmaz O
    Int J Cardiol; 2012 Mar; 155(3):418-23. PubMed ID: 21106264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of contrast-induced nephropathy with N-acetylcysteine or sodium bicarbonate in patients with ST-segment-myocardial infarction: a prospective, randomized, open-labeled trial.
    Thayssen P; Lassen JF; Jensen SE; Hansen KN; Hansen HS; Christiansen EH; Junker A; Ravkilde J; Thuesen L; Veien KT; Jensen LO
    Circ Cardiovasc Interv; 2014 Apr; 7(2):216-24. PubMed ID: 24714489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-acetylcysteine for the prevention of contrast-induced nephropathy in patients with pre-existing renal insufficiency or diabetes: a systematic review and meta-analysis.
    Kang X; Hu DY; Li CB; Ai ZS; Peng A
    Ren Fail; 2015 Nov; 37(10):297-303. PubMed ID: 26458505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of trimetazidine on preventing contrast-induced nephropathy after cardiac catheterization.
    Lian X; He W; Zhan H; Chen J; Tan N; He P; Liu Y
    Int Urol Nephrol; 2019 Dec; 51(12):2267-2272. PubMed ID: 31641999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography.
    Oldemeyer JB; Biddle WP; Wurdeman RL; Mooss AN; Cichowski E; Hilleman DE
    Am Heart J; 2003 Dec; 146(6):E23. PubMed ID: 14661012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.